Table 3.

Overall summary of TEAEs in HP cohorts receiving placebo or 35 mg, 100 mg, 200 mg or 300 mg of ARO-ANG3 (SADs) and cohorts receiving placebo or 100 mg, 200 mg or 300 mg of ARO-ANG3 (MADs)

	HPs (SAD)						HPs (MAD)
	Pooled placebo (n = 16)	Pooled active (n = 24)	ARO-ANG3 (35 mg) (n = 6)	ARO-ANG3 (100 mg) (n = 6)	ARO-ANG3 (200 mg) (n = 6)	ARO-ANG3 (300 mg) (n = 6)	Pooled Active (n = 12)	ARO-ANG3 (100 mg) (n = 4)	ARO-ANG3 (200 mg) (n = 4)	ARO-ANG3 (300 mg) (n = 4)
Number of TEAEs	34	65	12	13	23	17	44	17	6	21
Number of participants reporting at least one:
TEAE	14 (87.5%)	22 (91.7%)	5 (83.3%)	6 (100%)	6 (100%)	5 (83.3%)	10 (83.3%)	4 (100%)	2 (50.0%)	4 (100%)
Serious TEAE	1 (6.3%)	0	0	0	0	0	0	0	0	0
Severe TEAE	1 (6.3%)	0	0	0	0	0	0	0	0	0
Related TEAE	2 (12.5%)	4 (16.7%)	0	1 (16.7%)	2 (33.3%)	1 (16.7%)	2 (16.7%)	0	0	2 (50.0%)
Related serious TEAE	0	0	0	0	0	0	0	0	0	0
Related severe TEAE	0	0	0	0	0	0	0	0	0	0
TEAEs leading to drug/study withdrawal	0	0	0	0	0	0	0	0	0	0
Number of participants reporting TEAEs by severity:
Mild	12 (75.0%)	20 (83.3%)	5 (83.3%)	5 (83.3%)	6 (100%)	4 (66.7%)	10 (83.3%)	4 (100%)	2 (50.0%)	4 (100%)
Moderate	5 (31.3%)	5 (20.8%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	2 (33.3%)	0	0	0	0
Severe	1 (6.3%)	0	0	0	0	0	0	0	0	0
Number of participants reporting TEAEs by relationship to study treatment:
Not related	14 (87.5%)	22 (91.7%)	5 (83.3%)	6 (100%)	6 (100%)	5 (83.3%)	10 (83.3%)	4 (100%)	2 (50.0%)	4 (100%)
Possibly	2 (12.5%)	3 (12.5%)	0	1 (16.7%)	1 (16.7%)	1 (16.7%)	1 (8.3%)	0	0	1 (25.0%)
Probably	0	1 (4.2%)	0	0	1 (16.7%)	0	1 (8.3%)	0	0	1 (25.0%)

Notes: MedDRA version 21.1; related denotes possibly or probably.